Korro Bio (NASDAQ: KRRO) net income
Korro Bio reported a net loss of $117.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $83.6m. Earnings per share were −$12.48.
Korro Bio's best year of the last 8 was fiscal 2019. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$117.3m | — | −1,834.5% | −$12.48 |
| 2024 | −$83.6m | — | −3,680.4% | −$9.37 |
| 2023 | −$81.2m | — | — | −$53.08 |
| 2022 | −$58.0m | — | — | −$227.42 |
| 2021 | −$84.7m | — | −602.0% | — |
| 2020 | −$26.5m | — | −71.7% | — |
| 2019 | −$18.7m | — | −64.8% | — |
| 2018 | −$19.2m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Korro Bio net income compared with its sector
By net income for its latest fiscal year, Korro Bio ranks 352nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Korro Bio, −1,834.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 350th | MeiraGTx | −$114.2m | −140.3% |
| 351st | Absci | −$115.2m | −4,113.7% |
| 352nd | Korro Bio | −$117.3m | −1,834.5% |
| 353rd | Savara | −$118.8m | — |
| 354th | Voyager Therapeutics | −$119.7m | −296.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Korro Bio
- How much did Korro Bio earn in fiscal 2025?
- Korro Bio reported a net loss of $117.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $83.6m.
- What are the earnings per share of Korro Bio?
- They were −$12.48 in fiscal 2025, compared with −$9.37 in fiscal 2024.
- Where does Korro Bio rank in its sector by net income?
- It ranks 352nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Korro Bio come from?
- From the annual report (Form 10-K) that Korro Bio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Korro Bio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Korro Bio: the Korro Bio page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.